Advertisement

Journal of Neuro-Oncology

, Volume 104, Issue 1, pp 225–231 | Cite as

Prothrombotic state in glioblastoma multiforme: an evaluation of the procoagulant activity of circulating microparticles

  • Maria Teresa Sartori
  • Alessandro Della Puppa
  • Andrea Ballin
  • Graziella Saggiorato
  • Daniela Bernardi
  • Andrea Padoan
  • Renato Scienza
  • Domenico d’Avella
  • Giuseppe Cella
Clinical Study – Patient Study

Abstract

The relationship between venous thromboembolism (VTE) and cancer is supported by several pathogenetic factors, including circulating microparticles (MP) originating from different cells and often bearing tissue factor. Since VTE often complicates the clinical course of patients with glioblastoma multiforme (GBM; WHO grade IV astrocytoma) and the role of MPs in these patients population is still not clear, this prospective study was conducted to evaluate the procoagulant activity of circulating MP (MP activity) in GBM patients. We enrolled 61 GBM patients undergoing gross-total or subtotal surgical resection followed by combined radio-chemotherapy; 20 healthy volunteers were tested as controls. Blood samples for MP activity and hemostatic profiles were obtained before and then 1 week and 1, 4, and 7 months after surgery. GBM patients had significantly higher mean MP activity levels than healthy controls before and 7 days after surgery. During the follow-up, MP activity levels became significantly lower 1 and 4 months after surgery (P = 0.007 and P = 0.018, respectively) than prior to surgery, but this decrease was only seen in the subgroup achieving complete tumor resection. MP activity levels increased in 7 (63.6%) of 11 patients who developed VTE. The different incidence of the increase in MP activity levels between patients with and without VTE was statistically significant (χ 2 = 4.93, P = 0.026; relative risk 1.38, 95% CI 1.03–1.86). GBM patients may have an increase in MP-associated procoagulant activity that could contribute to any prothrombotic states and increases the likelihood of VTE complications; this procoagulant activity drops during control of disease.

Keywords

Brain tumors Glioblastoma multiforme Microparticles Prothrombotic state Venous thromboembolism 

References

  1. 1.
    Wun T, White RH (2009) Venous thromboembolism (VTE) in patients with cancer: epidemiology and risk factors. Cancer Invest 27:63–74PubMedCrossRefGoogle Scholar
  2. 2.
    Khorana AA (2010) Venous thromboembolism and prognosis in cancer. Thromb Res 125:490–493PubMedCrossRefGoogle Scholar
  3. 3.
    Falanga A (2009) The incidence and risk of venous thromboembolism associated with cancer and nonsurgical cancer treatment. Cancer Invest 27:105–115PubMedCrossRefGoogle Scholar
  4. 4.
    Milsom C, Rak J (2007) Tissue factor and cancer. Pathophysiol Haemost Thromb 36:160–176CrossRefGoogle Scholar
  5. 5.
    Zhang J, Ding J, Zhang X, Shao X, Hao Z (2005) Regulation of vascular endothelial growth factor production and angiogenesis by tissue factor in SGC-7901 gastric cancer cells. Cancer Biol Ther 4:769–772PubMedCrossRefGoogle Scholar
  6. 6.
    Zwicker JI, Furie BC, Furie B (2007) Cancer-associated thrombosis. Crit Rev Oncol Hematol 62:126–136PubMedCrossRefGoogle Scholar
  7. 7.
    Aharon A, Brenner B (2009) Microparticles, thrombosis and cancer. Best Pract Res Clin Haematol 22:61–69PubMedCrossRefGoogle Scholar
  8. 8.
    Davizon P, Lòpez JA (2009) Microparticles and thrombotic disease. Curr Opin Hematol 16:334–341PubMedCrossRefGoogle Scholar
  9. 9.
    CBTRUS (2009) 2009–2010 CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in eighteen states in 2002–2006. Central Brain Tumor Registry of the United States, Hinsdale, IL. www.cbtrus.org
  10. 10.
    Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466PubMedCrossRefGoogle Scholar
  11. 11.
    Marras LC, Geerts WH, Perry JR (2000) The risk of venous thromboembolism is increased throughout the course of malignant glioma. Cancer 89:640–646PubMedCrossRefGoogle Scholar
  12. 12.
    Semrad JT, O’Donnel R, Wun T et al (2007) Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg 106:601–608PubMedCrossRefGoogle Scholar
  13. 13.
    Franchini M, Montagnana M, Targher G, Manzato F, Lippi G (2007) Pathogenesis, clinical and laboratory aspects of thrombosis in cancer. J Thromb Thrombolysis 24:29–38PubMedCrossRefGoogle Scholar
  14. 14.
    Colin C, Voutsinos-Porche B, Nanni I et al (2009) High expression of cathepsin B and plasminogen activator inhibitor type-1 are strong predictors of survival in glioblastomas. Acta Neuropathol 118:745–754PubMedCrossRefGoogle Scholar
  15. 15.
    Rong Y, Belozerov VE, Tucker-Burden C et al (2009) Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein 1 transcriptional activity. Cancer Res 69:2540–2549PubMedCrossRefGoogle Scholar
  16. 16.
    Wells PS, Anderson DR, Bormanis J et al (1997) Value of assessment of pretest probability of deep-vein thrombosis in clinical management. Lancet 350:1795–1798PubMedCrossRefGoogle Scholar
  17. 17.
    Wells PS, Anderson DR, Rodger M et al (2000) Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost 83:416–420PubMedGoogle Scholar
  18. 18.
    Simanek R, Vormittag R, Hassler M et al (2007) Venous thromboembolism and survival in patients with high-grade glioma. Neuro Oncol 9:89–95PubMedCrossRefGoogle Scholar
  19. 19.
    Rodas RA, Fenstermaker RA, McKeever PE et al (1998) Correlation of intraluminal thrombosis in brain tumor vessels with postoperative thrombotic complications: a preliminary report. J Neurosurg 89:200–205PubMedCrossRefGoogle Scholar
  20. 20.
    Walsh DC, Kakkar AK (2001) Thromboembolism in brain tumors. Curr Opin Pulm Med 7:326–331PubMedCrossRefGoogle Scholar
  21. 21.
    Zwicker JI, Liebman HA, Neuberg D et al (2009) Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res 15:6830–6840PubMedCrossRefGoogle Scholar
  22. 22.
    Tesselaar ME, Romijn FP, Van Der Linden IK, Prins FA, Bertina RM, Osanto S (2007) Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost 5:520–527PubMedCrossRefGoogle Scholar
  23. 23.
    Hron G, Kollars M, Weber H et al (2007) Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb Haemost 97:119–123PubMedGoogle Scholar
  24. 24.
    Skog J, Wurdinger T, van Rijn S et al (2008) Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 10:1470–1476PubMedCrossRefGoogle Scholar
  25. 25.
    Tesselaar ME, Romijn FP, van der Linden IK, Bertina RM, Osanto S (2009) Microparticle associated tissue factor activity in cancer patients with and without thrombosis. J Thromb Haemost 7:1421–1423PubMedCrossRefGoogle Scholar
  26. 26.
    Manly DA, Wang J, Glover SL et al (2010) Increased microparticle tissue factor activity in cancer patients with venous thromboembolism. Thromb Res 125:511–512PubMedCrossRefGoogle Scholar
  27. 27.
    Khorana AA, Francis CW, Menzies KE et al (2008) Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost 6:1983–1985PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  • Maria Teresa Sartori
    • 1
  • Alessandro Della Puppa
    • 2
  • Andrea Ballin
    • 1
  • Graziella Saggiorato
    • 1
  • Daniela Bernardi
    • 3
  • Andrea Padoan
    • 3
  • Renato Scienza
    • 2
  • Domenico d’Avella
    • 2
  • Giuseppe Cella
    • 1
  1. 1.Department of Cardiologic, Thoracic and Vascular SciencesPadua University HospitalPadovaItaly
  2. 2.Department of NeurosurgeryPadua University HospitalPaduaItaly
  3. 3.Department of Laboratory MedicinePadua University HospitalPaduaItaly

Personalised recommendations